Short answer
PTC THERAPEUTICS, INC. (PTCT) filed an 8-K current report with the SEC on August 13, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). PTC selected as winning bidder for ST-920, a BLA-stage one-time AAV gene therapy candidate for Fabry disease.
PTC THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- PTC selected as winning bidder for ST-920, a BLA-stage one-time AAV gene therapy candidate for Fabry disease
- Acquisition from bankrupt Sangamo followed a competitive Chapter 11 auction
- ST-920 adds a potentially near-commercial Fabry therapy asset to PTC’s pipeline
- Transaction terms and closing conditions are detailed in Exhibit 99.1
Item 8.01 · Other Events
- Planned ST-920 acquisition: $111 million upfront plus up to $100 million FDA approval milestones
- Milestones include $80 million for accelerated approval and $20 million for traditional or full approval
- Closing targeted for late Q3 or early Q4 2026, pending bankruptcy court approval, antitrust review, and customary conditions
- Rolling FDA BLA submission expected in Q4 2026, supported by 52-week Phase 1/2 STAAR data
- International regulatory approval pursuit expands potential ST-920 commercialization scope
Item EX-99.1 · Exhibit EX-99.1
- Winning bid to acquire ST-920, a BLA-stage Fabry gene therapy, for $111 million upfront and up to $100 million milestones
- Acquisition expected to close late Q3 or early Q4 2026, pending bankruptcy court approval, antitrust review and definitive documentation
- Rolling FDA BLA submission targeted for completion in Q4 2026, with potential U.S. commercial launch in 2027
- Phase 1/2 data showed positive mean annualized eGFR slope at Week 52 and sustained enzyme activity up to 4.5 years
- Transaction leverages PTC’s existing rare-disease infrastructure while management expects no impact on cash-flow break-even target in 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PTC THERAPEUTICS, INC. 8-K filings
Get the next PTCT 8-K as it lands
Follow PTCT for push alerts, or ask the research agent what this filing means.